Mortality and the risk of malignancy in autoimmune liver diseases: A population‐based study in Canterbury, New Zealand
Mohamed I.F. Shariff, James Maggs, Michael A. Heneghan – 19 July 2012
Sustained virologic response: Is this equivalent to cure of chronic hepatitis C?
Leonard B. Seeff – 19 July 2012
Mouse model of primary biliary cirrhosis with progressive fibrosis: Are we there yet?
Yury Popov – 19 July 2012
Reply:
Jun Li, Lanjuan Li – 19 July 2012
Child‐Pugh score is altered by the albumin measurement method
Masanori Seimiya, Sayak Ohno, Haruna Yamamoto, Keiko Fujiwara, Toshihiko Yoshida, Yuji Sawabe, Kazuyuki Sogawa, Kazuyuki Matsushita, Osamu Yokosuka, Fumio Nomura – 19 July 2012
In Memoriam: Nelson Fausto, M.D.
Irwin M. Arias – 19 July 2012
CD40 inhibits replication of hepatitis C virus in primary human hepatocytes by c‐jun N terminal kinase activation independent from the interferon pathway
Sibylle J. Rau, Eberhard Hildt, Kiyoshi Himmelsbach, Robert Thimme, Takaji Wakita, Hubert E. Blum, Richard Fischer – 19 July 2012 – CD40, a member of the tumor necrosis factor receptor family, and its ligand, CD40L (CD154), are important regulators of the antiviral immune response. CD40L is up‐regulated on lymphocytes and CD40 on hepatocytes during infection with hepatitis C virus (HCV); we investigated the role of CD40 signaling during HCV replication in hepatocytes.
Intraportal transplantation of human bone marrow mesenchymal stem cells in pigs with fulminant hepatic failure
Suttiruk Jitraruch, Ragai R. Mitry, Anil Dhawan – 19 July 2012
Reply:
Da‐Qiang Li, Rakesh Kumar – 19 July 2012
A new feature of the MYH9‐related syndrome: Chronic transaminase elevation
Rémi Favier, Analisa DiFeo, Nathalie Hezard, Monique Fabre, Pierre Bedossa, John A. Martignetti – 17 July 2012